TARA PEARCY: Open Payments
NPI 1770952897 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$428 in 23 payments from 13 companies in 2025. Trend: 2023 $1,609 · 2024 $890 · 2025 $428
Food & beverage: $428
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $80 |
| Novo Nordisk Inc | 4 | $70 |
| GlaxoSmithKline, LLC. | 3 | $46 |
| Abbott Laboratories | 2 | $45 |
| Lilly USA, LLC | 2 | $39 |
| Astellas Pharma US Inc | 1 | $28 |
| Dexcom, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: VRAYLAR, PROCLAIM, JARDIANCE, Wegovy, TRELEGY ELLIPTA, Veozah, Dexcom G6 Transmitter, Ozempic.
Industry payments across IN — which companies pay providers there.
